{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:02Z","timestamp":1777934702988,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The use of Complementary Alternative Medicine (CAM) in patients with cancer is increasing. CAM is associated with potential toxicity and drug interactions, particularly with chemotherapy. Here, we report a case of cytolysis and hepatic cholestasis in a patient who was self-medicated with a mushroom powder-based alternative therapy containing\n                      <jats:italic>Agaricus blazei Murril<\/jats:italic>\n                      (ABM) during cancer treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A 43-year-old woman with metastatic colorectal cancer and hepatic metastases was admitted to our hospital for intravenous chemotherapy. Markers of hepatic grade 3 cytolysis and cholestasis were identified during the pretreatment consultation. The baseline results were within normal limits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and Outcome<\/jats:title>\n                    <jats:p>\n                      The chemotherapy was immediately canceled, and further tests were performed. After the investigation, the patient reported taking three mushroom powder-based capsules per day since November 2023. The dietary supplement contained ABM and\n                      <jats:italic>Hericium erinaceus (HE)<\/jats:italic>\n                      powder. After Pharmaceutical analysis, treatment with the supplement was discontinued, and the patient has not resumed. The changes in liver function were also favorable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In our case, given the improvement in liver function after CAM discontinuation, hepatic cytolysis appeared to be linked to ABM consumption despite the patient's liver metastases. Pharmaceutical analysis of CAM is essential to ensure the safety and optimization of cancer treatments. Patients should also communicate their CAMs to healthcare professionals and be aware of the consequences of consuming these dietary supplements. Finally, collaboration between pharmaceutical teams and oncologists is essential for optimal management of cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241280617","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:25:55Z","timestamp":1725330355000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Grade 3 cytolysis in a patient with metastatic colorectal cancer consuming a mushroom powder-based alternative therapy"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-0823","authenticated-orcid":false,"given":"Geoffrey","family":"Strobbe","sequence":"first","affiliation":[{"name":"Service de pharmacie, P\u00f4le produits de sant\u00e9, Centre Oscar Lambret, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Jeanjacquot","sequence":"additional","affiliation":[{"name":"Service de pharmacie, P\u00f4le produits de sant\u00e9, Centre Oscar Lambret, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Potey","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance, Service de pharmacologie, CHU Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Carnot","sequence":"additional","affiliation":[{"name":"P\u00f4le d\u2019oncologie m\u00e9dicale, Centre Oscar Lambret, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Marliot","sequence":"additional","affiliation":[{"name":"Service de pharmacie, P\u00f4le produits de sant\u00e9, Centre Oscar Lambret, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2019.01.004"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735411423920"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0223"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)31514-5"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e13108"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crfs.2022.10.029"},{"key":"e_1_3_3_8_2","unstructured":"AGARICUS MUSHROOM: overview uses side effects precautions interactions dosing and reviews https:\/\/www.webmd.com\/vitamins\/ai\/ingredientmono-1165\/agaricus-mushroom (accessed 6 August 2024)."},{"key":"e_1_3_3_9_2","unstructured":"Agaricus | Memorial Sloan Kettering Cancer Center https:\/\/www.mskcc.org\/cancer-care\/integrative-medicine\/herbs\/agaricus (2022 accessed 6 August 2024)."},{"key":"e_1_3_3_10_2","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud B","year":"1985","unstructured":"B\u00e9gaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111\u2013118.","journal-title":"Therapie"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_3_12_2","unstructured":"Fluorouracil. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548781\/ (2012 accessed 6 August 2024)."},{"key":"e_1_3_3_13_2","unstructured":"Irinotecan. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548037\/ (2012 accessed 6 August 2024)."},{"key":"e_1_3_3_14_2","unstructured":"Oxaliplatin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548456\/ (2012 accessed 6 August 2024)."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyl108"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-013-0359-0"},{"key":"e_1_3_3_17_2","first-page":"103","article-title":"Clinical utility of ABCL (Agalicus mushroom extract) treatment for C-type hepatitis","volume":"30","author":"Inuzuka H","year":"2002","unstructured":"Inuzuka H, Yoshida T. Clinical utility of ABCL (Agalicus mushroom extract) treatment for C-type hepatitis. Jpn Pharmacol Ther 2002; 30: 103\u2013107.","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_3_3_18_2","first-page":"35","article-title":"Agaricus blazei Murill extract abrogates CCl4-induced liver injury in rats","volume":"25","author":"Wu M-F","year":"2011","unstructured":"Wu M-F, Hsu Y-M, Tang M-C, et al. Agaricus blazei Murill extract abrogates CCl4-induced liver injury in rats. In Vivo 2011; 25: 35\u201340.","journal-title":"In Vivo"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2012.03.004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","unstructured":"Muthulingam M. Antihepatotoxic efficacy of mushroom Agaricus blazei Murrill against carbon tetrachloride induced liver damage in male albino Wistar rats. Epub ahead of print 22 April 2016. DOI: 10.5281\/ZENODO.1308666.","DOI":"10.5281\/ZENODO.1308666"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220920363"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06580-4"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231179899"},{"key":"e_1_3_3_24_2","unstructured":"Delga C. Arr\u00eat\u00e9 du 24 juin 2014 \u00e9tablissant la liste des plantes autres que les champignons autoris\u00e9es dans les compl\u00e9ments alimentaires et les conditions de leur emploi https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000029254516 (2014 accessed 24 January 2024)."},{"key":"e_1_3_3_25_2","unstructured":"Direction g\u00e9n\u00e9rale de la Concurrence de la Consommation et de la R\u00e9pression des fraudes. Liste des algues pouvant \u00eatre employ\u00e9es dans les compl\u00e9ments alimentaires https:\/\/www.economie.gouv.fr\/files\/files\/directions_services\/dgccrf\/securite\/produits_alimentaires\/Complement_alimentaire\/CA_ListeAlgues_Janvier2019.pdf?v=1702542231 (2019 accessed 25 January 2024)."},{"key":"e_1_3_3_26_2","unstructured":"Direction g\u00e9n\u00e9rale de la Concurrence de la Consommation et de la R\u00e9pression des fraudes. Liste des lichens pouvant \u00eatre employ\u00e9es dans les compl\u00e9ments alimentaires https:\/\/www.economie.gouv.fr\/files\/files\/directions_services\/dgccrf\/securite\/produits_alimentaires\/Complement_alimentaire\/CA_ListeLichens_Janvier2019.pdf?v=1702542231 (2019 accessed 25 January 2024)."},{"key":"e_1_3_3_27_2","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. Liste B des plantes m\u00e9dicinales utilis\u00e9es traditionnellement en l\u2019\u00e9tat ou sous forme de pr\u00e9paration dont les effets ind\u00e9sirables potentiels sont sup\u00e9rieurs au b\u00e9n\u00e9fice th\u00e9rapeutique attendu https:\/\/ansm.sante.fr\/uploads\/2021\/03\/25\/liste-b-des-plantes-medicinales-utilisees-traditionnellement.pdf (2021 accessed 24 January 2024)."},{"key":"e_1_3_3_28_2","first-page":"276","article-title":"Identifying drug interactions between enzalutamide and complementary alternative medications in a patient with metastatic prostate cancer: a case report","volume":"71","author":"Brownlee T","year":"2018","unstructured":"Brownlee T, Olson C, Deschamps M. Identifying drug interactions between enzalutamide and complementary alternative medications in a patient with metastatic prostate cancer: a case report. Can J Hosp Pharm 2018; 71: 276\u2013281.","journal-title":"Can J Hosp Pharm"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/nem007"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/27697061.2022.2103852"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-17581-5"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200310163491619"},{"key":"e_1_3_3_33_2","unstructured":"Agence nationale de s\u00e9curit\u00e9 sanitaire de l\u2019alimentation de l\u2019environnement et du travail. Compl\u00e9ments alimentaires\u202f: nos conseils pour limiter les risques https:\/\/www.anses.fr\/fr\/system\/files\/infographiecomplementsalimentaires.pdf (2019 accessed 6 August 2024)."},{"key":"e_1_3_3_34_2","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacie Oncologique. Recommandations S.F.P.O. Plantes et compl\u00e9ments alimentaires dans la prise en charge du patient atteint de cancer. Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacie Oncologique January 2020."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241280617","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241280617","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241280617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:19Z","timestamp":1777689019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241280617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10781552241280617"],"URL":"https:\/\/doi.org\/10.1177\/10781552241280617","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}